- Home
- LAB vs EXAI Comparison
LAB vs EXAI Comparison
Compare LAB & EXAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAB
- EXAI
- Stock Information
- Founded
- LAB 1999
- EXAI 2012
- Country
- LAB United States
- EXAI United Kingdom
- Employees
- LAB N/A
- EXAI 483
- Industry
- LAB Biotechnology: Laboratory Analytical Instruments
- EXAI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LAB Industrials
- EXAI Health Care
- Exchange
- LAB Nasdaq
- EXAI Nasdaq
- Market Cap
- LAB 642.1M
- EXAI 613.6M
- IPO Year
- LAB 2011
- EXAI 2021
- Fundamental
- Price
- LAB $1.58
- EXAI $4.69
- Analyst Decision
- LAB Strong Buy
- EXAI Hold
- Analyst Count
- LAB 2
- EXAI 4
- Target Price
- LAB $2.88
- EXAI $7.00
- AVG Volume (30 Days)
- LAB 2.5M
- EXAI 702.2K
- Earning Date
- LAB 10-30-2024
- EXAI 11-26-2024
- Dividend Yield
- LAB N/A
- EXAI N/A
- EPS Growth
- LAB N/A
- EXAI N/A
- EPS
- LAB N/A
- EXAI N/A
- Revenue
- LAB $155,902,000.00
- EXAI $22,877,630.00
- Revenue This Year
- LAB $62.60
- EXAI $156.33
- Revenue Next Year
- LAB $9.91
- EXAI N/A
- P/E Ratio
- LAB N/A
- EXAI N/A
- Revenue Growth
- LAB 48.23
- EXAI N/A
- 52 Week Low
- LAB $1.21
- EXAI $3.80
- 52 Week High
- LAB $3.04
- EXAI $7.91
- Technical
- Relative Strength Index (RSI)
- LAB 34.81
- EXAI 40.59
- Support Level
- LAB $2.12
- EXAI $4.80
- Resistance Level
- LAB $2.26
- EXAI $6.15
- Average True Range (ATR)
- LAB 0.17
- EXAI 0.38
- MACD
- LAB -0.04
- EXAI -0.01
- Stochastic Oscillator
- LAB 1.33
- EXAI 0.00
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
About EXAI Exscientia Plc
Exscientia PLC is engaged in the application of artificial intelligence (AI) and machine learning (ML) to the discovery and design of novel therapeutic compounds. The company's technology platform combines human and computational capabilities to accelerate the process of designing novel, safe, and efficacious compounds for clinical testing in humans. The company is focused on the discovery and development of small-molecule drug candidates.